[99mTc]diphosphonate uptake and hemodynamics in experimental arthritis: effect of naproxen in the canine carrageenan injection model.
The impact of naproxen treatment on juxta-articular hemodynamics and bone metabolism in experimental juvenile arthritis was studied in the articular carrageenan injection model. Unilateral gonarthritis was induced for 12 weeks in eight dogs receiving naproxen (dosage, 2 mg/kg) and eight controls. Regional blood flow was assessed by the microsphere method, plasma volume by the distribution space of [125I]fibrinogen, and bone metabolism by the 2-h uptake of [99mTc]diphosphonate ([99mTc]DPD). Synovial effusion was less prominent with naproxen treatment as judged by joint fluid volume and pressure. Naproxen reduced the arthritic capsular hyperemia, almost normalized a severe blood flow increase in patella and both juxta-articular epiphyses, ameliorated an expansion of plasma volume in the patella and the distal femoral epiphysis, and normalized an increased [99mTc]DPD uptake in subchondral femoral bone and the tibial cortex. Significantly increased arteriovenous shunting in the arthritic extremity was unaffected by naproxen. The study suggests that long-term cyclooxygenase inhibition offers protection against hemodynamic and metabolic changes in juxta-articular bone secondary to synovial inflammation.
Hansen
E S
ES
Department of Orthopedics, University of Aarhus, Denmark.
He
S Z
SZ
Søballe
K
K
Kjølseth
D
D
Henriksen
T B
TB
Hjortdal
V E
VE
Bünger
C
C
D000818:Animals; D001168:Arthritis / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism*; D001842:Bone and Bones / Q000098:blood supply / Q000378:metabolism / Q000502:physiology; D002199:Capillary Permeability / Q000502:physiology; D002351:Carrageenan / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D004285:Dogs; D006132:Growth Plate / Q000098:blood supply / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D006706:Homeostasis; D007267:Injections; D008863:Microspheres; D009288:Naproxen / Q000494:pharmacology* / Q000627:therapeutic use; D012039:Regional Blood Flow; D013667:Technetium / Q000493:pharmacokinetics*; D017556:Technetium Compounds
D004164:Diphosphonates; D017556:Technetium Compounds; D009288:Naproxen; D013667:Technetium; C029045:technetium Tc 99m diphosphonate; D002351:Carrageenan